Hormone Replacement Therapy (HRT) Clinical Trials

Clinical trials related to Hormone Replacement Therapy (HRT) Procedure

Clinical Efficacy Study of Jinfeng Pill in the Treatment of Perimenopausal Syndrome

Status: Recruiting
Location: See all (3) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 4
SUMMARY

Perimenopausal syndrome (PMS) is a common condition affecting women during the transition to menopause, often causing hot flashes, sweating, insomnia, anxiety, depression, fatigue, and reduced quality of life. Current hormone replacement therapy can improve symptoms, but long-term use may increase the risk of breast cancer and cardiovascular complications. Therefore, safer and more effective alternative treatments are needed. Jinfeng Pill is a traditional Chinese medicine patented drug that has been widely used in gynecological disorders. Previous studies suggest that it may help regulate hormone balance, improve ovarian function, and reduce inflammation. Recent research has also shown that intestinal bacteria (gut microbiota) may influence estrogen metabolism through the gut microbiota-estrogen axis, which could play an important role in perimenopausal symptoms. This study is a randomized, double-blind, placebo-controlled clinical trial designed to evaluate the effectiveness and safety of Jinfeng Pill in women with perimenopausal syndrome. Eligible participants will be randomly assigned to receive either Jinfeng Pill or a placebo for 12 weeks. Researchers will assess changes in menopausal symptoms, mood, sleep, and quality of life using standardized questionnaires and laboratory tests. In addition, the study will explore how Jinfeng Pill may regulate gut microbiota, β-glucuronidase (β-GUS) activity, short-chain fatty acids (SCFAs), inflammatory factors, and estrogen-related indicators. The findings may provide new evidence for the clinical use of traditional Chinese medicine in the treatment of perimenopausal syndrome and help clarify its underlying biological mechanisms.

Eligibility
Participation Requirements
Sex: Female
Minimum Age: 45
Maximum Age: 55
Healthy Volunteers: f
View:

• Female patients aged 45-55 years;

• Menstrual disorders (prolonged menstrual cycle or hypomenorrhea) lasting for more than 3 months, or amenorrhea for 2-12 months;

• Presence of vasomotor symptoms (hot flashes, sweating), somatic symptoms (insomnia, fatigue, headache, paresthesia), psychological symptoms (anxiety, depression), or urogenital symptoms (dyspareunia, vaginal dryness, urinary tract infection);

• Serum follicle-stimulating hormone (FSH) \> 10 IU/L, or decreased estradiol (E2) levels;

• No use of HRT or other medications for perimenopausal symptoms in the past 2 months;

• Intact uterus and bilateral adnexa, not surgically removed;

• Voluntary participation and signing of informed consent;

• Modified Kupperman Index (KI score) ≥ 6, indicating mild or above symptoms.

Locations
Other Locations
China
Hubei Maternal and Child Health Hospital,Tongji Medical College of Huazhong University of Science and Technology
RECRUITING
Wuhan
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
RECRUITING
Wuhan
Wuhan Children's Hospital (Wuhan Maternal and Child Health Hospital),Tongji Medical College of Huazhong University of Science and Technology
RECRUITING
Wuhan
Contact Information
Primary
Xiaohu Xu
hermanxu@163.com
+8613006111902
Time Frame
Start Date: 2026-05-10
Estimated Completion Date: 2028-05-01
Participants
Target number of participants: 100
Treatments
Placebo_comparator: Placebo group
Placebo
Experimental: Jinfeng Pill group
Jinfeng Pill
Sponsors
Leads: Tongji Hospital

This content was sourced from clinicaltrials.gov